Breast cancer arising within fibroadenoma: collective analysis of case reports in the literature and hints on treatment policy

Table 2 Demographic and clinical features ^a

Characteristics (N=30)	Data
Mean age (range), yr	46.9 (27 to 80)
Mean tumor size (range), cm	2.46 (0.8 to 5.1)
Female gender, n (%)	30 (100%)
Mean tumor follow-up duration (range) months	61.2 (0.5 to 600)
Histology^b (N =30), n (%)
DCIS	7 (23.3%)
LCIS	5 (16.7%)
IDC	16 (53.3%)
ILC	4 (13.3%)
TNM stage (N =30), n (%)
TisN0M0	10 (33.3%)
T1aN0M0	1 (3.3%)
T1bN0M0	3 (10.0%)
T1aN1M0	1 (3.3%)
Unclear	15 (30%)
Operation method (N =30), n (%)
BCS	20 (66.7%)
Mastectomy	9 (30.0%)
No data	1 (3.3%)
Lymph node dissection (N =30), n (%)
Axillary clearance	8 (26.7%)
Sentinel lymph node dissection	11 (36.7%)
Not done	1 (3.3%)
No data	10 (33.3%)
Lymph node (N =30), n (%)
Metastasis	5 (16.7%)
Negative	16 (53.3%)
No data	9 (30.0%)
Receptor status
ER + (n =16)	11 (68.8%)
PR + (n =16)	10 (62.5%)
HER2+ (n =10)	1 (10.0%)
Further management
Chemotherapy (n =10)	4 (40.0%)
Hormone therapy (n =10)	6 (60.0%)
Radiation therapy (n =11)	5 (45.5%)
Outcome
Average follow-up (range), months	21.9 (5 to 59)
Recurrence (n =16)	1 (6.3%)
Distant metastasis^c (n =16)	1 (6.3%)

^aBCS, Breast-conserving surgery; DCIS, Ductal carcinoma in situ; ER, Estrogen receptor; HER2, Human epidermal growth factor receptor 2; IDC, Invasive ductal carcinoma; ILC, Invasive lobular carcinoma; LCIS, Lobular carcinoma in situ; PR, Progesterone receptor; TNM, Tumor, node, metastasis. ^bOne patient had both LCIS and IDC, and another had both DCIS and LCIS. ^cDistant metastasis was noted at cancer diagnosis.

ISSN: 1477-7819